COMP <GO>
DXCM vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
DexCom Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: DXCM 6
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: DXCM
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
roic
21.60%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 74.80% | -14.70 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 21.60% | 20.70% | +0.90 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 15.3x | +9.90 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 3.42% | +0.15 | DXCM | /fcf-yield <GO> |
| Operating Margin | 19.60% | 34.30% | -14.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 28.10% | -10.20 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 1.30% | +14.30 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 5.19 | +1.95 | DXCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | DXCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 56.9 | -9.11 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.92 | +0.18 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 18.4x | +11.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $361.02B | -$330.86B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | MRK REV | DXCM GROSS % | MRK GROSS % | DXCM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $65.01B | 60.1% | 74.8% | $1.08B | $12.36B |
| FY 2024 | $4.03B | $64.17B | 60.5% | 76.3% | $630.7M | $18.10B |
| FY 2023 | $3.62B | $60.12B | 44.0% | 44.0% | $585.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
MRK // BETA 0.92